As of 5 Jul 2026, ORCHID PHARMA share price is ₹956.40. The stock opened at ₹983.20, compared to its previous close of ₹979.30. During today's trading session, ORCHID PHARMA share price moved in the range of ₹944.30 to ₹986.15, with an average price of ₹965.22 for the day. Looking at its last 52-week, the stock has touched a low of ₹480.00 and a high of ₹1,094.00. On the performance front, ORCHID PHARMA share price has increased by 20.35% over the last six months and is up 27.94% on a year-on-year basis.
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹921.93 | ₹819.37 | ₹665.90 | ₹559.56 |
| Other Income | ₹27.47 | ₹30.86 | ₹19.43 | ₹9.00 |
| Total Revenue | ₹949.40 | ₹850.23 | ₹685.33 | ₹568.56 |
| Total Expenses | ₹853.84 | ₹758.29 | ₹669.29 | ₹625.46 |
| Profit Before Tax | ₹95.56 | ₹91.95 | ₹55.25 | -₹56.90 |
| Tax | -₹0.19 | -₹3.12 | ₹0.00 | ₹0.00 |
| Profit After Tax | ₹95.76 | ₹95.06 | ₹55.25 | -₹56.90 |
| EPS - Basic | ₹19.65 | ₹19.06 | ₹11.35 | -₹0.48 |
| EPS - Diluted | ₹19.65 | ₹19.06 | ₹11.35 | -₹0.48 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹99.46 | ₹89.05 | ₹46.32 | -₹1.95 |
| Income before WC changes | ₹128.69 | ₹133.20 | ₹97.70 | ₹34.81 |
| Change in Assets | -₹105.00 | -₹55.43 | -₹87.17 | ₹5.69 |
| Change in Liabilities | -₹3.54 | ₹47.59 | ₹8.10 | ₹53.87 |
| Change in WC | -₹108.53 | -₹7.84 | -₹79.06 | ₹59.57 |
| Cash flow from Operations | ₹19.22 | ₹125.99 | ₹18.34 | ₹92.47 |
| Cash flow from Investing | -₹26.93 | -₹312.03 | -₹31.21 | ₹112.94 |
| Cash flow from Financing | ₹25.22 | ₹167.04 | ₹31.17 | -₹216.80 |
| Total Cash Flow | ₹17.51 | -₹19.00 | ₹18.29 | -₹11.39 |
| Cash (Start of the year) | ₹3.60 | ₹22.60 | ₹4.31 | ₹15.69 |
| Cash (End of the year) | ₹21.11 | ₹3.60 | ₹22.60 | ₹4.31 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹880.50 | ₹763.12 | ₹724.20 | ₹712.91 |
| Current Assets | ₹807.42 | ₹790.75 | ₹501.01 | ₹397.65 |
| Total Assets | ₹1,687.91 | ₹1,553.87 | ₹1,225.21 | ₹1,110.56 |
| Current Liabilities | ₹285.57 | ₹259.97 | ₹371.89 | ₹240.78 |
| Net Current Asset | ₹521.85 | ₹530.78 | ₹129.12 | ₹156.87 |
| Non-Current Liabilities | ₹135.06 | ₹124.43 | ₹164.67 | ₹222.40 |
| Equity Capital | ₹1,267.29 | ₹1,169.47 | ₹688.65 | ₹647.38 |
| Total Equity & Liabilities | ₹1,687.91 | ₹1,553.87 | ₹1,225.21 | ₹1,110.56 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹921.93 | ₹819.37 | ₹665.90 | ₹556.97 |
| Other Income | ₹31.93 | ₹30.39 | ₹19.43 | ₹9.00 |
| Total Revenue | ₹953.86 | ₹849.76 | ₹685.33 | ₹565.98 |
| Total Expenses | ₹847.37 | ₹758.23 | ₹669.29 | ₹618.75 |
| Profit Before Tax | ₹106.48 | ₹91.52 | ₹55.25 | -₹52.77 |
| Tax | ₹0.00 | -₹3.23 | ₹0.00 | ₹0.00 |
| Profit After Tax | ₹106.48 | ₹94.75 | ₹55.25 | -₹52.77 |
| EPS - Basic | ₹20.99 | ₹19.59 | ₹13.28 | -₹1.18 |
| EPS - Diluted | ₹20.99 | ₹19.59 | ₹13.28 | -₹1.18 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹106.48 | ₹91.52 | ₹54.19 | -₹4.81 |
| Income before WC changes | ₹130.01 | ₹133.21 | ₹108.29 | ₹33.43 |
| Change in Assets | -₹100.25 | -₹45.55 | -₹104.38 | ₹9.91 |
| Change in Liabilities | -₹1.33 | ₹42.33 | ₹9.78 | ₹48.13 |
| Change in WC | -₹101.58 | -₹3.22 | -₹94.60 | ₹58.04 |
| Cash flow from Operations | ₹27.48 | ₹130.73 | ₹13.39 | ₹89.57 |
| Cash flow from Investing | -₹37.35 | -₹315.81 | -₹26.70 | ₹112.93 |
| Cash flow from Financing | ₹25.44 | ₹167.07 | ₹31.17 | -₹216.80 |
| Total Cash Flow | ₹15.58 | -₹18.01 | ₹17.86 | -₹14.30 |
| Cash (Start of the year) | ₹0.29 | ₹18.31 | ₹0.45 | ₹14.75 |
| Cash (End of the year) | ₹15.87 | ₹0.29 | ₹18.31 | ₹0.45 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹910.19 | ₹769.91 | ₹729.46 | ₹711.12 |
| Current Assets | ₹786.39 | ₹782.29 | ₹493.79 | ₹383.07 |
| Total Assets | ₹1,696.58 | ₹1,552.20 | ₹1,223.26 | ₹1,094.19 |
| Current Liabilities | ₹237.47 | ₹209.67 | ₹326.63 | ₹193.83 |
| Net Current Asset | ₹548.92 | ₹572.62 | ₹167.16 | ₹189.24 |
| Non-Current Liabilities | ₹135.06 | ₹124.21 | ₹164.67 | ₹222.40 |
| Equity Capital | ₹1,324.05 | ₹1,218.32 | ₹731.96 | ₹677.95 |
| Total Equity & Liabilities | ₹1,696.58 | ₹1,552.20 | ₹1,223.26 | ₹1,094.19 |
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.
ORCHID PHARMA share price is ₹956.40 as on 03 Jul, 2026, 15:40 IST.
In the last 1 year, ORCHID PHARMA delivered a return of 27.94%. The ORCHID PHARMA share price hit a high of ₹1,094.00 and low of ₹480.00.
The Mutual Fund Shareholding in ORCHID PHARMA was 19.43% at the end of Mar 2026.
The 52-week high and low of ORCHID PHARMA share is ₹1,094.00 and ₹480.00 as of 03 Jul, 2026.
The market capitalisation of ORCHID PHARMA is ₹4,957.79 Crores as on 03 Jul, 2026.
The stock symbol of ORCHID PHARMA is ORCHPHARMA on the NSE, 524372 on the BSE, and the ISIN is INE191A01027.
ORCHID PHARMA shares closed yesterday at ₹979.30 on NSE & ₹977.50 on BSE
To buy ORCHID PHARMA shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
No, shares of ORCHID PHARMA or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell ORCHID PHARMA shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
The PE and PB ratio of ORCHID PHARMA is 241.36 and 3.85 respectively, as on 03 Jul, 2026, 15:40 IST.